[zzeeman]

No one needs a vaccine for coronaviruses.

Can not be repeated enough.

The evil ones are trying to take advantage of the vulnerable.

[ransomnote]

So they are using the FAKE PCR test, which assures fake results as it has in all the other 'vaccines'. Oh this phase III trial lasts a whole 42 days - when 12 years is usually required to determine safety and efficacy. This is the smallest phase III trial I've seen to date. 
As usual, they exclude persons who had Covid, who are pregnant or have co-morbidities for the trials - but note the other vaccines are forced on pregnant women and those with co-morbidities. I read about the death of a 99 year old man in hospice who hadn't eaten for a week (Pfizer or MOderna, I forget). But that's not a cohort the 'trials' ever tested.

The info below is from Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 - Full Text View - ClinicalTrials.gov

 

Study Type  :	Interventional  (Clinical Trial)
Estimated Enrollment  :	13000 participants
Official Title:	a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.
Actual Study Start Date  :	June 7, 2021
Estimated Primary Completion Date  :	July 7, 2022
Estimated Study Completion Date  :	August 7, 2022

 

Primary Outcome Measures  :

1. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
   Per 1000 person-years of follow-up
2. Percentage of participants reporting Serious adverse events or medically attended adverse events [ Time Frame: From dose 1 through one year after the last dose ]
3. Geometric mean of Anti-S IgG concentrations at each time point in a subset of participants [ Time Frame: days 0, 42, 180, 365 after vaccination ]
4. Geometric mean of SARS-CoV-2 serum neutralizing titers by Plaque reduction neutralization test (PRNT) at each time point in a subset of participants [ Time Frame: days 0, 42 after vaccination ]

Secondary Outcome Measures  :

1. Percentage of participants reporting solicited local and systemic reactions [ Time Frame: 7 days after each study vaccination ]
2. Percentage of participants reporting unsolicited vaccine-related ≥ Grade 2 adverse events [ Time Frame: 28 days after each study vaccination ]
3. Proportion of participants achieving ≥4-fold rise of Anti-S IgG at each time point in a subset of participants [ Time Frame: days 0,42, 180, 365 after vaccination ]
4. T-cell responses (intracellular cytokine staining) [ Time Frame: days 0, 42 after vaccination ]
   Change from baseline in the cell-mediated immune response in a subset of participants
5. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} asymptomatic case of COVID-19 [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
   Per 1000 person-years of follow-up
6. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} mild case of COVID-19 [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
   Per 1000 person-years of follow-up
7. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} moderate to severe case of COVID-19 [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
   Per 1000 person-years of follow-up
8. Number of participants who death due to covid-19 confirmed with (RT-PCR) positive [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
   Per 1000 person-years of follow-up

Eligibility Criteria

Ages Eligible for Study:	18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

• Be a male or female 18 years of age or older.
• For females: Be of non-childbearing potential or willing to use appropriate contraceptive measures for 30 days prior to vaccination through 6 months after completion of the vaccine series.
• Willingness to provide a signed, printed, and dated informed consent form.
• Able and willing to participate in all activities in the clinical trial.
• Participants with HIV, HBV, HCV should have a health record, determined to be stable for 6 months prior to the screening.

Exclusion Criteria:

• Participants with unstable pre-existing medical conditions over the three months before enrollment (condition that has worsened to require hospitalization or significant changes in therapy).
• Planned administration/administration of a vaccine not foreseen by the study protocol from within 45 days before the first dose of study vaccine.
• Previous vaccination with any Covid-19 vaccine.
• History of COVID-19 disease.
• History of allergic reactions or anaphylaxis to previous immunizations or allergies to any components of the vaccine.
• Planning to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase through 6 months after the second immunization.
• History of bleeding disorders/hemostasis or use of anticoagulants.
• Currently having cancer or undergoing cancer treatment.
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 3 months prior to the first vaccine dose (inhaled and topical steroids are allowed).
• Women who are pregnant or breastfeeding.